Emory University
Ticiana Leal, MD is associate professor and serves as director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Board certified in medical oncology and palliative care, Dr. Leal specializes in caring for patients with lung cancer, mesothelioma and thymic malignancies at Winship Cancer Institute . Dr. Leal's clinical research focuses on clinical trials of immunotherapy or targeted therapy agents to treat cancers of the lung.
Dr. Leal has authored or coauthored numerous peer-reviewed original research articles, book chapters and posters. She serves as associate editor and as a member of the executive editorial board of The Journal of the National Comprehensive Cancer Network. She also serves as Lung Cancer Section Editor of Current Treatment Options in Oncology and on the editorial advisory boards of Cancer and The Brazilian Journal of Oncology.
Dr. Leal holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, Eastern Cooperative Oncology Group, European Society of Medical Oncology, Society for Immunotherapy of Cancer, and International Association for the Study of Lung Cancer. She is the NCI LUNG-MAP Chair, ECOG-ACRIN representative.
Amgen (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; AstraZeneca (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Consultant; Bayer (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Boehringer-Ingelheim (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Consultant; Daiichi-Sankyo (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Consultant; Eisai (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Consultant; EMD Serono (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Genentech (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Janssen (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Consultant; Jazz Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Consultant; Lilly (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Merck (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Mirati (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Consultant; Novocure (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Regeneron (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Roche (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Takeda (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board
Saturday, October 15, 2022
3:05 PM – 4:10 PM
Saturday, October 15, 2022
3:10 PM – 3:25 PM
Saturday, October 15, 2022
3:50 PM – 4:10 PM
Thursday, November 10, 2022
9:00 AM – 10:00 AM
Thursday, November 10, 2022
9:05 AM – 9:20 AM
Thursday, November 10, 2022
9:35 AM – 10:00 AM
Thursday, November 10, 2022
11:20 AM – 12:30 PM
Thursday, November 10, 2022
11:25 AM – 11:45 AM
Thursday, November 10, 2022
12:05 PM – 12:30 PM